| Literature DB >> 27335431 |
Kunihiko Aizawa1, Salim Elyas2, Damilola D Adingupu3, Francesco Casanova3, Kim M Gooding3, W David Strain2, Angela C Shore3, Phillip E Gates3.
Abstract
Previous studies have reported a vasoconstrictor response in the radial artery during a cuff-induced low-flow condition, but a similar low-flow condition in the brachial artery results in nonuniform reactivity. This variable reactivity to low-flow influences the subsequent flow-mediated dilatation (FMD) response following cuff-release. However, it is uncertain whether reactivity to low-flow is important in data interpretation in clinical populations and older adults. This study aimed to determine the influence of reactivity to low-flow on the magnitude of brachial artery FMD response in middle-aged and older individuals with diverse cardiovascular risk profiles. Data were analyzed from 165 individuals, divided into increased cardiovascular risk (CVR: n = 115, 85M, 67.0 ± 8.8 years) and healthy control (CTRL: n = 50, 30M, 63.2 ± 7.2 years) groups. Brachial artery diameter and blood velocity data obtained from Doppler ultrasound were used to calculate FMD, reactivity to low-flow and estimated shear rate (SR) using semiautomated edge-detection software. There was a significant association between reactivity to low-flow and FMD in overall (r = 0.261), CTRL (r = 0.410) and CVR (r = 0.189, all P < 0.05) groups. Multivariate regression analysis found that reactivity to low-flow, peak SR, and baseline diameter independently contributed to FMD along with sex, the presence of diabetes, and smoking (total R(2) = 0.450). There was a significant association between reactivity to low-flow and the subsequent FMD response in the overall dataset, and reactivity to low-flow independently contributed to FMD These findings suggest that reactivity to low-flow plays a key role in the subsequent brachial artery FMD response and is important in the interpretation of FMD data.Entities:
Keywords: Brachial artery; cardiovascular disease; endothelial function; shear stress; ultrasound
Mesh:
Year: 2016 PMID: 27335431 PMCID: PMC4923229 DOI: 10.14814/phy2.12808
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Selected characteristics and medical history of the study participants
| Overall | Control | CVR | |
|---|---|---|---|
| Age, years | 65.0 (62.0–72.0) | 64.0 (60.0–67.0) | 66.0 (62.8–74.0) |
| Sex (M/F), | 115/50 | 30/20 | 85/30 |
| BMI, kg m−2 | 27.1 ± 4.0 | 25.0 ± 3.1 | 28.1 ± 4.0 |
| Total CHOL, mmol L−1 | 4.55 (3.78–5.50) | 5.50 (4.95–6.20) | 4.10 (3.48–4.80) |
| LDL CHOL, mmol L−1 | 2.47 (1.77–3.31) | 3.29 (2.75–3.91) | 2.13 (1.60–2.78) |
| HDL CHOL, mmol L−1 | 1.43 (1.16–1.75) | 1.72 (1.39–2.04) | 1.33 (1.09–1.59) |
| TG, mmol L−1 | 1.03 (0.82–1.53) | 0.92 (0.74–1.29) | 1.10 (0.85–1.60) |
| FG, mmol L−1 | 5.25 (4.80–5.70) | 5.00 (4.80–5.50) | 5.35 (4.70–5.80) |
| Systolic BP, mmHg | 140.7 ± 16.2 | 139.1 ± 16.3 | 141.4 ± 16.1 |
| Diastolic BP, mmHg | 79.4 ± 8.9 | 79.1 ± 9.0 | 79.6 ± 8.92 |
| Stroke/TIA, | 89 | 0 | 89 |
| CAD, | 14 | 0 | 14 |
| PAD, | 2 | 0 | 2 |
| Type 2 Diabetes, | 18 | 0 | 18 |
| Hypertension, | 83 | 0 | 83 |
| Dyslipidemia, | 92 | 0 | 92 |
| Current smoking, | 8 | 2 | 6 |
| Current Medications | |||
| Biguanides, | 14 | 0 | 14 |
| Sulfonylureas, | 2 | 0 | 2 |
| DPP‐4 inhibitors, | 1 | 0 | 1 |
| Insulin, | 1 | 0 | 1 |
|
| 5 | 1 | 4 |
|
| 19 | 0 | 19 |
| ACE inhibitors, | 41 | 0 | 41 |
| ARBs, | 13 | 0 | 13 |
| CCBs, | 29 | 0 | 29 |
| Nitrates, | 2 | 0 | 2 |
| Diuretics, | 26 | 0 | 26 |
| Statins, | 93 | 0 | 93 |
| Anticoagulants, | 2 | 0 | 2 |
| Antiplatelets, | 90 | 1 | 90 |
| HRT, | 1 | 1 | 1 |
CVR, increased cardiovascular risk group; BMI, body mass index; CHOL, cholesterol; LDL, low‐density lipoprotein; HDL, high‐density lipoprotein; TG, triglycerides; FG, fasting glucose; BP, blood pressure; TIA, transient ischemic attack; CAD, coronary artery disease; PAD, peripheral artery disease; DPP‐4, dipeptidyl peptidase‐4; ACE, angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; HRT, hormone replacement therapy.
Data are presented as means ± SD or median (interquartile range).
Significantly different from the control group (P < 0.05).
Prescribed for benign prostate enlargement.
prescribed for a condition associated with postorthopedic surgery.
Selected brachial artery structural and hemodynamic indices of the study participants
| Overall | Control | CVR | |
|---|---|---|---|
| D base, mm | 3.85 (3.38–4.27) | 3.85 (3.06–4.35) | 3.90 (3.44–4.26) |
| D low‐flow, mm | 3.80 ± 0.66 | 3.71 ± 0.76 | 3.83 ± 0.61 |
| SR diff, sec−1 | 48.6 (34.1–77.3) | 45.2 (31.4–72.5) | 49.4 (34.6–78.2) |
| Low‐flow reactivity, % | −0.38 ± 1.59 | −0.35 ± 1.69 | −0.39 ± 1.55 |
| D peak, mm | 3.94 ± 0.64 | 3.86 ± 0.74 | 3.98 ± 0.59 |
| FMD, % | 3.26 (2.04–4.91) | 3.37 (1.83–5.82) | 3.12 (2.18–4.80) |
| Composite reactivity, % | 4.07 (2.14–5.21) | 4.20 (2.42–5.27) | 3.86 (1.93–5.10) |
| SR peak, sec −1 | 819.2 (676.5–1021.1) | 874.2 (686.9–1053.1) | 803.6 (663.0–963.4) |
| SR aucttp, au | 25 559 (21 122–31 760) | 24 468 (19 696–29 776) | 25 795 (21 675–32 777) |
| TTP, sec | 50.0 (40.0–65.0) | 40.0 (35.0–56.3) | 50.0 (40.0–70.0) |
CVR, increased cardiovascular risk group; D base, baseline diameter; D low‐flow, diameter during low‐flow; SR diff, difference in shear rate; D peak, peak diameter; FMD, flow‐mediated dilatation; SR peak, peak shear rate; SR aucttp, shear rate area under the curve until peak dilatation; TTP, time to peak dilatation.
Data are presented as means ± SD or median (interquartile range).
Figure 1Univariate association between reactivity to low‐flow and FMD in the brachial artery in the overall dateset (A), CTRL (B), and CVR (C). Ln‐ denotes a log‐transformation. Note that a constant (2) was added to each FMD value before log‐transformation to make all the values positive and nonzero.